stockrowBiogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. (BIIB) Debt to equity
Biogen Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.4×, up 0.0× from fiscal 2025 (0.3×). Over the past ten years it has ranged from 0.3× (fiscal 2024) to 0.7× (fiscal 2015); the current reading is higher than 27% of that period. That is below the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.3× | 26.62% |
| FY2024 | 0.3× | (40.70%) |
| FY2023 | 0.5× | (2.22%) |
| FY2022 | 0.5× | (18.06%) |
| FY2021 | 0.6× | (17.61%) |
| FY2020 | 0.7× | 107.87% |
| FY2019 | 0.3× | (26.61%) |
| FY2018 | 0.5× | (3.31%) |
| FY2017 | 0.5× | (12.27%) |
| FY2016 | 0.5× | (22.80%) |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.4× | (0.36%) |
| Jun 2026 | 0.4× | 14.71% |
| Mar 2026 | 0.3× | (2.09%) |
| Dec 2025 | 0.3× | (0.23%) |
| 43 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| SNY Sanofi compare | 0.2× |
| BIIB Biogen Inc. | 0.4× |
| AZN AstraZeneca PLC compare | 0.6× |
| NVO Novo Nordisk A/S compare | 0.6× |
| PFE Pfizer Inc. compare | 0.7× |
| GSK GSK PLC Sponsored ADR compare | 1.3× |
| BMY Bristol Myers Squibb Company compare | 1.8× |
| GILD Gilead Sciences, Inc. compare | 2.0× |
| AMGN Amgen Inc. compare | 3.8× |
| Drug Manufacturers General industry median | 0.6× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement